Introduction {#s1}
============

Spondyloarthritis (SpA) represents a group of inflammatory rheumatic diseases whose main clinical feature is inflammation of the axial spine.[@R1] The focus of the current study is axial spondyloarthritis (AxSpA). Although the precise aetiology of SpA remains unknown, there is mounting evidence of complex interplay of genetic, environmental and immunological factors.[@R1] Despite the success of genome-wide association studies (GWAS) in ankylosing spondylitis (AS), where 25 genetic loci have reached a level of significance, the genetic contribution identified only explains 25% of heritability.[@R2] This 'missing heritability' is attributed, at least in part, to inherent limitations of GWAS studies, which primarily assess one type of genetic variation (ie, single nucleotide polymorphisms) in a case--control approach, and consequently limits searches to common variants. Rare variants, which might also contribute to SpA susceptibility, occur in approximately 1% of the population, and many are likely to be specific to ethnic groups, isolates or families.[@R6]

That SpA clearly clusters within families, evident from the occurrence of multiple affected individuals within a family[@R7] [@R8] and the high recurrence ratio among siblings,[@R9] is a compelling reason to investigate the genetics in this setting. The objective of this study is to discover rare, highly penetrant pathogenic variants in the pathogenesis of AxSpA using a large, well-characterised, multigenerational family and exome sequencing of affected and unaffected family members.

Methods {#s2}
=======

Study population {#s2a}
----------------

A large Caucasian multiplex AxSpA family of North European Ancestry from Newfoundland, Canada, was identified in a university-based rheumatology clinic. All available family members were invited to participate in this study and were systematically assessed using a standardised protocol by an experienced rheumatologist (PR). The Spondyloarthritis Consortium of Canada provided clinical and radiographic data, as well as DNA samples for the replication cohorts.

B-cell lines {#s2b}
------------

Acid citrate dextrose anticoagulated whole blood was collected from family members. Lymphoblastoid B-cell lines (BCL) were generated by Epstein--Barr transformation of peripheral blood B cells as described previously.[@R10]

Nucleic acid extraction {#s2c}
-----------------------

DNA was extracted from EDTA anticoagulated whole blood using a traditional salting-out method.[@R11] BCL pellets were resuspended in 0.5 mL TRIzol (Life Technologies) and RNA extracted as per manufacturer\'s instructions and dissolved in Molecular Biology grade water. RNA quality and quantity measures are provided in the online supplementary methods.

*HLA-B\*27* testing {#s2d}
-------------------

Targeted analysis of the *HLA-B* locus located on 6p21.3 was performed using a commercially available kit (LABType SSO HLA-B locus kit) on a Luminex 100/200 platform as per manufacturer\'s instructions (One Lambda).

Exome sequencing {#s2e}
----------------

Samples were sequenced targeting whole genome exons with an average coverage of 110× using Illumina HiSeq 2000. The mapping of reads was aligned using Burrows Wheeler Alignment V.0.7.10, and the genome analysis toolkit (GATK) V.1.1.28 was used to call variants against the reference genome. To reduce false positive calling, 40% support reads was used as a cut-off for alternative allele. Analysis was carried out to detect rare mutations that segregate only within the affected individuals. Annovar (April 2014 version) was used for variant annotation.

Fragment analysis {#s2f}
-----------------

DNA was amplified using specific primers for *SEC16A* and *MAMDC4* using a standard touchdown reaction on a GeneAmp PCR System 9700 (Applied Biosystems). PCR primers, PCR product preparation, capillary electrophoresis and results analysis are provided in the online supplementary methods.

Linkage analysis {#s2g}
----------------

A phased VCF file for the nuclear family (ie, II-1, II-2 and III-2) was obtained using the GATK software (V.3.3). VCFtools (V.0.1.12b) were used to calculate pairwise r^2^, D and D′ for the genetic variants identified on chromosome 9 from 138 000 000 to 141 000 000 base pairs (GRCh37) of the nuclear subfamily.[@R12] This genomic region includes the two novel deletions in *SEC16A* and *MAMDC4*. Linkage disequilibrium (LD) between *SEC16A* and *MAMDC4* in the general population was investigated using DistilLD Database[@R13] and GLIDERS.[@R14]

Quantitative PCR {#s2h}
----------------

Real-time PCR was performed using TaqMan Gene Expression Assays for *SEC16A* (Hs_00389570_m1) and *GAPDH* (Hs_99999905_m1) from Life Technologies. Samples were tested as per manufacturer\'s instructions and run on a StepOnePlus (Applied Biosystems). Triplicate samples were analysed using the comparative threshold cycle (ΔΔ^CT^) method and results normalised to *GAPDH*. Statistical analyses were performed by One-way analysis of variance (ANOVA) and unpaired t test with GraphPad Prism V.6.04.

Western blot {#s2i}
------------

RIPA lysates were prepared from BCL as described previously.[@R15] Protein determination was performed using a bicinchoninic acid protein assay kit according to manufacturer\'s instructions (Thermo Scientific). Primary and secondary antibodies as well as the imaging system used are indicated in the online supplementary methods. Each sample was expressed as a ratio to tubulin, then compared with the proband. Statistical analyses were performed using one-way ANOVA and unpaired t test with GraphPad Prism V.6.04.

Circular dichroism spectroscopy {#s2j}
-------------------------------

Detailed information on protein expression and purification prior to circular dichroism (CD) spectroscopy is indicated in the online supplementary methods. CD spectra in the far-ultraviolet range were recorded using a Jasco-810 spectrapolarimeter. The temperature (25°C) was controlled, and the scanning speed of the instrument was set at 100 nm/min with normal sensitivity. A water-jacketed cell (light path=0.5 mm) was used, and spectra were collected between 190 and 260 nm. Baselines were established using the appropriate buffers, and 30 spectra were collected and averaged for each sample.

Results {#s3}
=======

A well-characterised, multigenerational family with AxSpA was investigated to identify rare genetic variants ([figure 1](#ANNRHEUMDIS2014206484F1){ref-type="fig"}). All affected family members carried the *HLA-B\*27* allele ([table 1](#ANNRHEUMDIS2014206484TB1){ref-type="table"}). Exome sequencing was subsequently performed on selected family members with a minimum coverage of 110×. An exome sequencing analysis pipeline (see online supplementary figure S1) was used for the detection of genetic variants (see online supplementary table S1). Subsequent filtering and analysis revealed a 9 base pair in-frame deletion in *SEC16A* and a 20 base pair out-of-frame deletion in *MAMDC4* ([figure 2](#ANNRHEUMDIS2014206484F2){ref-type="fig"}A)*,* which segregated with AxSpA in the family ([table 1](#ANNRHEUMDIS2014206484TB1){ref-type="table"}). The chromosome 9 deletions located within exon 3 of *SEC16A* and exon 5 of *MAMDC4* were confirmed bidirectionally using Sanger sequencing in family members primarily from generation II ([figure 2](#ANNRHEUMDIS2014206484F2){ref-type="fig"}B, C) with 7/9 of the clinically diagnosed AxSpA individuals carrying both deletions in synteny ([table 1](#ANNRHEUMDIS2014206484TB1){ref-type="table"}). In contrast, both deletions were not in synteny for all unaffected family members tested in generation II. Closer inspection revealed that family members diagnosed with AxSpA who carried both deletions in synteny in addition to the *HLA-B\*27* allele had an earlier age of symptom onset (20.2±3.14 vs 35.0±0; p=0.0074; t test with Welch\'s correction) compared with family members diagnosed with AxSpA who carried the *HLA-B\*27* allele but both deletions not in synteny.

###### 

Clinical information, genotype data (*HLA-B27*, *SEC16A* and *MAMDC4*) of the large, well-characterised, multigenerational family with numerous individuals clinically diagnosed with and without AxSpA

  Family member   Diagnosis (Dx)   Extra-articular features   Age of onset (years)   *SEC16A/MAMDC4* status   *HLA-B27* status
  --------------- ---------------- -------------------------- ---------------------- ------------------------ ------------------
  I-2             Unaffected       --                         N/A                    Het/Het                  Negative
  II-1            AxSpA            None                       26                     Het/Het                  Positive
  II-2            Unaffected       --                         N/A                    Wt/Wt                    Negative
  II-4            AxSpA            None                       12                     Het/Het                  Positive
  II-6            AxSpA            Psoriasis                  27                     Het/Het                  Positive
  II-8            AxSpA            Lupus                      12                     Het/Het                  Positive
  II-9            AxSpA            None                       30                     Het/Het                  Positive
  II-11           Unaffected       --                         N/A                    Wt/Wt                    Positive
  II-13           AxSpA            Iritis                     35                     Wt/Wt                    Positive
  II-15           Unaffected       N/A                        N/A                    Wt/Wt                    Positive
  II-17           AxSpA            Crohn\'s                   35                     Wt/Wt                    Positive
  II-19           AxSpA            Iritis                     N/A                    Het/Het                  Positive
  II-21           Unaffected       --                         N/A                    Wt/Wt                    Positive
  II-23           Unaffected       --                         N/A                    Wt/Wt                    Positive
  III-2           AxSpA            None                       14                     Het/Het                  Positive

Detailed information is provided for only the second generation and one individual (III-2) in the third generation.

AxSpA, axial spondyloarthritis; Het, heterozygous for deletion; N/A, information not available; Wt, wild-type (no deletion).

![A large multigenerational family with several members clinically diagnosed with and without axial spondyloarthritis (AxSpA). Diagnosed comorbidities such as psoriasis, iritis and Crohn\'s disease are also indicated. The proband (II-1) in this family is indicated by an arrowhead.](annrheumdis-2014-206484f01){#ANNRHEUMDIS2014206484F1}

![Deletions located within *SEC16A* and *MAMDC4*. (A) Full exome sequencing analysis revealed a 9 base pair deletion located within *SEC16A* and a 20 base pair deletion located within *MAMDC4* that segregated only within affected family members. Both deletions were confirmed using bidirectional Sanger sequencing of the proband (II-1). (B) The top panel is a representative chromatogram illustrating a portion of the wild-type sequence of *SEC16A* exon 3. The lower panel is a representative chromatogram illustrating a portion of *SEC16A* exon 3 with the in-frame deletion indicated by an arrow. (C) The top panel is a representative chromatogram illustrating a portion of the wild-type sequence of *MAMDC4* exon 5. The lower panel is a representative chromatogram illustrating a portion of *MAMDC4* exon 5 with the out-of-frame deletion indicated by an arrow.](annrheumdis-2014-206484f02){#ANNRHEUMDIS2014206484F2}

The frequency of each deletion was assessed in publically available datasets to determine if either deletion represents a rare genomic event. Mining of the 1000 Genomes, National Heart, Lung, and Blood Institute, and in-house sequencing datasets (7849 total controls) revealed a frequency of 0.4% and 1.2% for the *SEC16A* and *MAMDC4* deletion, respectively. To determine if either deletion represents a rare variant private to the study family, the frequency of the *SEC16A* and *MAMDC4* deletion was assessed using fragment analysis in unrelated AxSpA cases and compared with unaffected controls (see online supplementary table S2). The *SEC16A* deletion produced a frequency of 0.87% in unrelated AxSpA cases compared with 0.84% in unaffected controls (p=0.925). Similarly, the *MAMDC4* deletion produced a frequency of 1.38% in unrelated AxSpA cases compared with 1.41% in unaffected controls (p=0.926). Interestingly, both *SEC16A* and *MAMDC4* deletions were only detected together in the AxSpA study family and were not detected together in over 900 unrelated AxSpA cases or in 1150 unaffected controls.

Linkage analysis, which was performed to estimate the degree of linkage between the *SEC16A* and *MAMDC4* loci in the family, revealed that there is very strong LD (r^2^=1; D′=1) between the *SEC16A* and *MAMDC4* loci within the nuclear subfamily (see online supplementary table S3; [figure 3](#ANNRHEUMDIS2014206484F3){ref-type="fig"}A, B). In contrast, *SEC16A* and *MAMDC4* loci occur in separate LD blocks in the general population (see online supplementary table S4; [figure 3](#ANNRHEUMDIS2014206484F3){ref-type="fig"}C, D).

![Linkage analysis was performed using VCFtools to estimate the degree of linkage between the *SEC16A* and *MAMDC4* loci in the family and the general population. Analysis revealed that there is very strong linkage disequilibrium (LD) (r^2^=1; D′=1) between the *SEC16A* and *MAMDC4* loci within the nuclear subfamily. The X and Y axes are genomic positions on chromosome 9, the deletions in *SEC16A* and *MAMDC4* are located at positions 139370954 and 139748276, respectively. White represents a score of 0 and black represents a score of 1. Linkage disequilibrium cluster plots illustrating (A) r^2^ values and (B) the D′ values for the nuclear family. In contrast, (C) *SEC16A* and (D) *MAMDC4* loci occur in distinctly separate LD blocks in the general population.](annrheumdis-2014-206484f03){#ANNRHEUMDIS2014206484F3}

Gene and protein expression analysis was performed on select family members to determine if the *SEC16A* deletion affects gene transcription or translation. *SEC16A* gene expression was not significantly different in AxSpA individuals carrying the deletion compared with AxSpA individuals not carrying the deletion (p=0.2383; [figure 4](#ANNRHEUMDIS2014206484F4){ref-type="fig"}A). Western analysis revealed that Sec16A protein expression was not significantly different in AxSpA individuals carrying the deletion compared with AxSpA individuals not carrying the deletion (p=0.3849; [figure 4](#ANNRHEUMDIS2014206484F4){ref-type="fig"}B, C).

![*SEC16A* gene and SEC16A protein expression is not altered among individuals with the deletion mutation. (A) The relative expression of *SEC16A* mRNA was determined by real-time quantitative PCR (qPCR) analysis of patient-derived B-cell lines. *SEC16A* relative expression was compared between family members with wild-type (Wt) and heterozygous (Het) genotypes for the *SEC16A* and *MAMDC4* deletion. Results are expressed as mean±SEM and analysed by t test. (B) Sec16A protein expression of RIPA lysates from patient-derived B-cell lines of family members. Blots are representative of three separate experiments. Densitometric analysis was performed to determine the level of SEC16A expression relative to tubulin as a loading control. (C) Comparison of protein expression between family members with Wt and Het genotypes for the *SEC16A* deletion. Results are expressed as mean±SEM and analysed by t test.](annrheumdis-2014-206484f04){#ANNRHEUMDIS2014206484F4}

CD spectroscopy was performed to determine if the *SEC16A* deletion affects protein structure. Given that the *SEC16A* deletion is located in a region that encodes the N-terminus of Sec16A, a 40 amino acid region around the deletion was initially selected using PONDR-FIT. CD spectroscopy demonstrated that the wild-type and deletion peptides have a disordered secondary structure ([figure 5](#ANNRHEUMDIS2014206484F5){ref-type="fig"}A). In the presence of trifluoroethanol (TFE), the wild-type peptide adopted a secondary structure, whereas the peptide encoding the *SEC16A* deletion clearly lacked secondary structure. A disordered secondary structure was also confirmed using CD spectroscopy on the complete N-terminus peptide ([figure 5](#ANNRHEUMDIS2014206484F5){ref-type="fig"}B). In the presence of TFE, the wild-type full-length N-terminus adopted an alpha helical secondary structure; however, the full-length N-terminus encoding the *SEC16A* deletion (369--371) had a similar spectra profile but exhibited decreased signal amplitude.

![Circular dichroism (CD) spectroscopy performed on the 40 amino acid peptide and the complete N-terminus peptide of Sec16A. (A) CD spectroscopy of the 40 amino acid peptides demonstrated that both the Sec16A wild-type (o; black) and mutant (Δ; green) peptides have a secondary structure that is disordered. The wild-type peptide (□; blue) in the presence of trifluoroethanol (TFE) adopted a distinct secondary structure (broad peak from 230 to 200 nm and the disappearance of the negative peak at 195 nm). The mutant peptide (+; red) in the presence of TFE failed to adopt a distinct secondary structure. (B) CD spectroscopy of the complete N-terminus also demonstrated that both the Sec16A wild-type (o; black) and mutant (Δ; green) peptides have a secondary structure that is disordered. The wild-type peptide (□; blue) in the presence of TFE adopted a distinct secondary structure, whereas the mutant peptide (+; red) in the presence of TFE had a spectra similar in shape to the wild-type peptide, but exhibited a decreased signal amplitude. Each CD spectroscopy graph is representative of the average of 30 spectra.](annrheumdis-2014-206484f05){#ANNRHEUMDIS2014206484F5}

Finally, experiments were conducted to investigate if the *SEC16A* deletion disrupts co-localisation with Sec31A. Immunofluorescence microscopy using patient-derived BCLs from individuals with the *SEC16A* deletion demonstrated no qualitative change in Sec16A or Sec31A expression alone or in their co-localisation (see online supplementary figure S2).

Discussion {#s4}
==========

A well-characterised, multigenerational AxSpA family was investigated using exome sequencing and *HLA-B\*27* genotyping. Investigation was primarily limited to individuals within generation II as those individuals were available for precise clinical phenotyping. Individuals from generation III (except III-2) were not systematically assessed given their lack of availability to participate in the study, their relatively young age and the fact that their assignment of phenotype could change with time, which could confound data analysis. The perfect concordance of exome and Sanger sequencing excludes *SEC16A* and *MAMDC4* deletions as technical artefacts. Both deletions were inherited maternally (I-2), whereas the *HLA-B\*27* allele was presumably inherited paternally (I-1). Furthermore, given that I-2 is *HLA-B\*27* negative and that all 12 siblings in generation II are *HLA-B27* positive, it was deduced that I-1 was homozygous for the *HLA-B27* allele.

That linkage analysis revealed that there is very strong LD (r^2^=1; D′=1) between the *SEC16A* and *MAMDC4* loci within the nuclear subfamily and extended family members, whereas *SEC16A* and *MAMDC4* loci occur in distinctly separate LD blocks in the general population, which suggests that a different genomic architecture is present on 9q34.3 in this family compared with the general population; a finding possibly attributed to a large intergenic deletion or a recombination event not detectable by exome sequencing.

That numerous variables affect genotype--phenotype correlation in complex disease including reduced penetrance, variable expressivity, epistatic interactions and gene--environment interactions, it was not surprising that a perfect genotype--phenotype correlation was not achieved in all family members within generation II. Interestingly, the discordant genotype--phenotype relationship occurred in two individuals (ie, II-13 and II-17) that had less severe disease and a significantly later age of onset. The apparent discrepancy in population frequency between publically available datasets and the replication cohort is largely attributed to differences in coverage depth as gaps in the public datasets result in detection bias.

*SEC16A* contains 32 exons and encodes a 250 kDa protein comprising 2357 amino acids. The deletion results in the removal of three amino acids (small for gestational age) within the N-terminus, producing a mildly truncated transcript. *MAMDC4* contains 27 exons and encodes a 131 kDa protein (ie, endotubin) comprising 1216 amino acids. The deletion results in a premature termination codon (p.Val185Glyfs\*2), producing a severely truncated transcript containing only 187 amino acids, which is likely rapidly degraded by nonsense-mediated RNA decay (NMD). The primary focus of this study was to increase our understanding of how the *SEC16A* deletion contributes to pathogenicity given that (1) Sec16A functions as a scaffold protein with multiple central roles for coat protein complex II (COPII) vesicle formation and trafficking,[@R16] which may be of relevance to AxSpA pathogenesis; (2) a recent study in patients with inflammatory bowel disease (IBD) where exome sequencing identified multiple rare novel *SEC16A* variants;[@R6] (3) very little is known regarding the structure and function of the *MAMDC4* encoded protein;[@R20] and (4) the *MAMDC4* deletion is a target for NMD.

That the *SEC16A* deletion failed to alter gene or protein expression was not unexpected considering this deletion failed to produce a severely premature transcript therefore avoiding NMD, suggesting that a deleterious effect may be attributed to a mechanism independent of transcription or translation. Interestingly, the Sec16A N-terminus, which is quite disordered and possesses many evolutionary conserved disordered binding regions, is critical for COPII assembly.[@R21] [@R22] Results from CD spectroscopy using a 40 amino acid peptide of the Sec16A N-terminus (selected using PONDR-FIT[@R23]) with and without the deletion confirmed that both were intrinsically disordered. That TFE induced a distinct structure only with the wild-type peptide and not with the deletion peptide suggests that the deletion of three amino acids within a short peptide is sufficient to interfere with local secondary structure. CD spectroscopy of peptides comprising the complete N-terminus of Sec16A confirmed the results generated with the shorter peptide, and further indicated that the deletion is sufficient to interfere with secondary structure of the entire N-terminus. The decreased signal amplitude could result either from a perturbation in the structure of the deletion peptide or from a global destabilisation that produces an increased population of unfolded protein at equilibrium with a well-folded population.[@R24] Therefore, the *SEC16A* deletion may alter the ability of Sec16A to adopt an ordered structure in the presence of its receptor proteins, which may contribute to AxSpA in this family.

That Sec16 serves as a template for the Sec13--Sec31 coat, that both Sec16 and Sec31 share an ACE1 element and that direct interactions between Sec16 and Sec31 facilitate COPII assembly,[@R18] the effect of the *SEC16A* deletion on Sec31A co-localisation was investigated to better define the functional impact of the *SEC16A* deletion. That the *SEC16A* deletion was without effect on Sec31A co-localisation could suggest that a mechanism completely independent of Sec31A (eg, another component of the COPII coat) might be altered by the *SEC16A*-induced conformational change. For example, Sec31A may be recruited to the COPII assembly site, but the direct interaction with Sec16A might be impaired due to the deletion-induced conformational change. Future investigations using electron microscopy are warranted to address this possibly.

Unfortunately, studies investigating the dysfunction of Sec16A are lacking. However, a role for Sec16 in AxSpA pathogenesis may involve several possible mechanisms attributed to known interactions of Sec16A with nuclear factor kappa B,[@R25] TRAF3,[@R26] COPII-binding protein Bap31[@R27] and the MAPK pathway.[@R28] [@R29] Any one or multiple interactions may be negatively disrupted by the *SEC16A*-induced conformational change.

This study is not without limitations. As exome sequencing does not interrogate the complete genome, other events occurring outside the coding region (eg, distal enhancer, silencers) might also contribute to disease susceptibility in the study family. For example, the 400 kb region between *SEC16A* and *MAMDC4* contains an extremely large number of common variants of which many, if not most, are non-coding and are unlikely to have been picked up by the sequencing method used. Any of these variants could be the true disease-associated variant if in LD with the *SEC16A* and/or *MAMDC4* variants. Although the study design with respect to exome coverage depth and variant filtering was very conservative, the possibility exists that a pathogenic variant could have been missed. Since the effect of the *SEC16A* deletion was investigated functionally using only B cells grown in culture, the contribution of other cell types and the effect of the *SEC16A* deletion in those cell types are unknown.

That the population frequency of *SEC16A* and *MAMDC4* was low and not significantly different between unrelated AxSpA cases and controls, that both deletions were only detected together in the study family or in a large replication cohort (n=2050), that *SEC16A* and *MAMDC4* are in strong LD within the family and that family members diagnosed with AxSpA who carried both deletions in synteny in addition to the *HLA-B\*27* allele had an earlier age of symptom onset suggest that it is the presence of the private rare deletions in synteny that increases susceptibility and modifies the disease course in the affected family members who carry the *HLA-B\*27* allele. Interestingly, that affected family members carried both *SEC16A* and *MAMDC4* deletions and tested positive for *HLA-B27* also raises the possibility that their encoded proteins are involved in HLA-B27 transport. We do acknowledge that the finding that AxSpA family members who carried both deletions in synteny in addition to the *HLA-B\*27* allele had an earlier age of symptom onset compared with AxSpA family members who carried the *HLA-B\*27* allele but both deletions not in synteny is based on a very small number of patients, and so this genotype--phenotype correlation needs to be independently validated.

While this is the first report identifying potentially rare novel private pathogenic deletions in *SEC16A* and *MAMDC4* in AxSpA, a study employing exome sequencing of patients with IBD identified rare novel *SEC16A* variants. Specifically, a non-synonymous rare *SEC16A* variant (c.1480G\>C; p.G494R) predicted to be pathogenic was identified.[@R6] Interestingly, that variant was located in exon 3, the same exon as the deletion discovered in this study. The finding of rare pathogenic *SEC16A* variants in a related autoimmune disease and the conformational change induced by deletion of three highly conserved amino acid residues from the intrinsically disordered and critically important N-terminus of Sec16A in the current study supports a pathogenic role of *SEC16A* in AxSpA pathogenesis in this family. That *MAMDC1,* which has been identified as a candidate gene for systemic lupus erythematosus,[@R30] is a paralog of *MAMDC4,* and that the *MAMDC4* deletion is predicted to be pathogenic through NMD, is consistent with pathogenicity. However, a better understanding of the effect of the *MAMDC4* deletion on structure and function of endotubin warrants further investigation. In conclusion, this study highlights the importance of private rare variants in AS/AxSpA and suggests that a proportion of the heritability unaccounted for by common variation may reside with higher risk rare variants, and even private variants.
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